1MIKA F, KATSUYA M, SACHIKO N,et al. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ( "Iressa" ) and trastuzumab ( " Herceptin" ) [ J ]. Int J Radiat Oncol Biol Phys,2006,61 (2) :528 -536.
2ILARIA B, SERGIO B, CLAUDIA C, et al. Targeting of EGFR tyrosine kinase by ZD1839 ( " Iressa" ) in an-drogen-responsive prostate cancer in vitro[J]. Mol Genet Metabol ,2006 , 88 ( 2 ) :114 - 122.
3AL-HAZZAA A, BOWEN I D, RANDERSON P,et al. The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC- 15 cells [ J ]. Cell Prolif,2005,38 (2) :77 - 86.
4LING Y H, LI T, YUAN Z, et al. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 upregulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines[ J]. Mol Pharmacol,2007,72(2) :248 -258.
5BRACARDA S, CASERTA C, SORDINI L, et al. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib [ J ]. Ann Oncol,2007,18(6) :22 -25.
6STRUMBERG D. Preclinical and clinical development of the oral muhikinase inhibitor sorafenib in cancer treatment[ J]. Drugs Today (Barc) ,2005,41 (12) :773 -784.
7CHOW L Q, ECKHARDT S G. Sunitinib: from rational design to clinical efficacy [ J ]. J Clin Oncol,2007,25 ( 7 ) : 884 - 896.
8ROBERTS W G, WHALEN P M, SODERSTROM E, et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451 [ J ]. Cancer Res, 2005,65 ( 3 ) : 957 - 966.
9BERTINO P, PORTA C, BARBONE D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment:imatinib mesylate with gemcitabine or pemetrexed [ J ]. Thorax,2007,62 (8) :690 - 695.
